Antibiotics in Otolaryngology: A Practical Approach

  • Alyssa R. LetourneauEmail author


This chapter provides an overview of common antibiotics encountered in otolaryngology with a summary of microbial spectrum of activity, clinical indications, and adverse effects. A clinical approach to choosing antibiotics is outlined. Antibiotic stewardship is highlighted, with an emphasis on the optimal use of antibiotics.


Antibiotics Antibiotic stewardship Antibiotic spectrum Multidrug-resistant organisms Antibiotic allergies 


  1. 1.
    Fleming-Dutra KE, Mangione-Smith R, Hicks LA. How to prescribe fewer unnecessary antibiotics: talking points that work with patients and their families. Am Fam Physician. 2016;94(3):200–2.PubMedGoogle Scholar
  2. 2.
    Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. CS239559-B. Atlanta, GA: US Department of Health and Human Services. Public Health Service. Centers for Disease Control and Prevention (CDC); 2013.Google Scholar
  3. 3.
    Cosgrove SE, Seo SK, Bolon MK, Sepkowitz KA, Climo MW, Diekema DJ, et al. Evaluation of postprescription review and feedback as a method of promoting rational antimicrobial use: a multicenter intervention. Infect Control Hosp Epidemiol. 2012;33(4):374–80.CrossRefPubMedGoogle Scholar
  4. 4.
    Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA, File TM Jr, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA. 2016;315(17):1864–73.CrossRefPubMedGoogle Scholar
  5. 5.
    Hersh AL, Fleming-Dutra KE, Shapiro DJ, Hyun DY, Hicks LA. Outpatient antibiotic use target-setting workgroup. Frequency of first-line antibiotic selection among US ambulatory care visits for otitis media, sinusitis, and pharyngitis. JAMA Intern Med. 2016;176(12):1870–2.CrossRefPubMedGoogle Scholar
  6. 6.
    Gross AE, Van Schooneveld TC, Olsen KM, Rupp ME, Bui TH, Forsung E, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother. 2014;58(9):5262–8.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):575–82.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Jackson MA, Schutze GE, Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. Pediatrics. 2016;138(5):e20162706.CrossRefPubMedGoogle Scholar
  9. 9.
    Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a review. Clin Ther. 2014;36(11):1489–1511.e4.CrossRefPubMedGoogle Scholar
  10. 10.
    Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Hematol Oncol Clin North Am. 2011;25(1):117–38.CrossRefPubMedGoogle Scholar
  11. 11.
    Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. Pharmacotherapy. 2015;35(11):1052–62.CrossRefPubMedGoogle Scholar
  12. 12.
    Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US Emergency Department visits for outpatient adverse drug events, 2013-2014. JAMA. 2016;316(20):2115–25.CrossRefPubMedGoogle Scholar
  13. 13.
    Lee CE, Zembower TR, Fotis MA, Postelnick MJ, Greenberger PA, Peterson LR, et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med. 2000;160(18):2819–22.CrossRefPubMedGoogle Scholar
  14. 14.
    Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259–73.CrossRefGoogle Scholar
  15. 15.
    Jeffres MN, Narayanan PP, Shuster JE, Schramm GE. Consequences of avoiding beta-lactams in patients with beta-lactam allergies. J Allergy Clin Immunol. 2016;137(4):1148–53.CrossRefPubMedGoogle Scholar
  16. 16.
    Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin “allergy” in hospitalized patients: a cohort study. J Allergy Clin Immunol. 2014;133(3):790–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Blumenthal KG, Shenoy ES, Varughese CA, Hurwitz S, Hooper DC, Banerji A. Impact of a clinical guideline for prescribing antibiotics to inpatients reporting penicillin or cephalosporin allergy. Ann Allergy Asthma Immunol. 2015;115(4):294–300.e2.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Sferra TJ, Hernandez AV, Donskey CJ. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951–61. Scholar
  19. 19.
    Dingle KE, Didelot X, Quan TP, Eyre DW, Stoesser N, Golubchik T, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis. 2017;17:411.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–20.CrossRefPubMedGoogle Scholar
  21. 21.
    Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.CrossRefPubMedGoogle Scholar
  22. 22.
    Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372(21):1996–2005.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Hoberman A, Paradise JL, Rockette HE, Kearney DH, Bhatnagar S, Shope TR, et al. Shortened antimicrobial treatment for acute otitis media in young children. N Engl J Med. 2016;375(25):2446–56.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ban KA, Minei JP, Laronga C, Harbrecht BG, Jensen EH, Fry DE, et al. American College of Surgeons and Surgical Infection Society: surgical site infection guidelines, 2016 update. J Am Coll Surg. 2017;224(1):59–74.CrossRefPubMedGoogle Scholar
  25. 25.
    Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195–283.CrossRefGoogle Scholar
  26. 26.
    Berrios-Torres SI, Umschied CA, Bratzler DW, et al. Centers for Disease Prevention and Control guidelines for prevention of surgical site infection, 2017. JAMA Surg. 2017;152(8):784–91.CrossRefPubMedGoogle Scholar
  27. 27.
    Romano A, Gaeta F, Valluzzi RL, et al. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins. J Allergy Clin Immunol. 2016;138:179–86.CrossRefPubMedGoogle Scholar
  28. 28.
    Patriarca G, Schiavino D, Lombardo C, et al. Tolerability of aztreonam in patients with IgE-mediated hypersensitivity to beta-lactams. Int J Immunopathol Pharmacol. 2008;21:375–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Perez Pimiento A, Gomez Martinez M, Minguez Mena A, Trampal Gonzalez A, de Paz Arranz S, Rodriguez Mosquera M. Aztreonam and ceftazidime: evidence of in vivo cross allergenicity. Allergy. 1998;53(6):624–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Handelsman JA, Nasr SZ, Pitts C, King WM. Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides. Pediatr Pulmonol. 2017;52:1157. Scholar
  31. 31.
    Hsiao CB, Dryja D, Abbatessa L, Patel PH. Staphylococcus aureus antimicrobial susceptibility of abscess samples from adults and children from the Kaleida Health System in western New York State, 2003 to 2006. J Clin Microbiol. 2010;48(5):1753–7.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Sutter DE, Milburn E, Chukwuma U, Dzialowy N, Maranich AM, Hospenthal DR. Changing susceptibility of staphylococcus aureus in a US Pediatric Population. Pediatrics. 2016;137(4)CrossRefPubMedGoogle Scholar
  33. 33.
    DeMuri GP, Sterkel AK, Kubica PA, et al. Macrolide and clindamycin resistance in group a streptococci isolated from children with pharyngitis. Pediatr Infect Dis J. 2017;36:342–4.CrossRefPubMedGoogle Scholar
  34. 34.
    Kuster SP, Rudnick W, Shigayeva A, Green K, Baqi M, Gold WL, et al. Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance. Clin Infect Dis. 2014;59(7):944–52.CrossRefPubMedGoogle Scholar
  35. 35.
    Ben-David D, Schwaber MJ, Adler A, Masarwa S, Edgar R, Navon-Venezia S, et al. Persistence and complex evolution of fluoroquinolone-resistant Streptococcus pneumoniae clone. Emerg Infect Dis. 2014;20(5):799–805.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    United States Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Silver Spring, MD: US Food and Drug Administration; 2016.Google Scholar
  37. 37.
    Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309(6):559–69.CrossRefGoogle Scholar
  38. 38.
    Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14(8):696–705.CrossRefGoogle Scholar
  39. 39.
    Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Jardin CG, Palmer HR, Shah DN, Le F, Beyda ND, Jiang Z, et al. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect. 2013;85(1):28–32.CrossRefPubMedGoogle Scholar
  41. 41.
    Stevens VW, Nelson RE, Schwab-Daugherty EM, Khader K, Jones MM, Brown KA, et al. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with clostridium difficile infection. JAMA Intern Med. 2017;177:546.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Infectious DiseasesMassachusetts General Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations